GABOR FEKETE: Open Payments
NPI 1306535919 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,387 in 40 payments from 12 companies in 2025. Trend: 2023 $458 · 2024 $1,913 · 2025 $2,387
Food & beverage: $2,387
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $593 |
| Intra-Sana Laboratories | 12 | $262 |
| ABBVIE INC. | 3 | $260 |
| Amgen Inc. | 6 | $247 |
| United Therapeutics Corporation | 3 | $241 |
| Astellas Pharma US Inc | 3 | $149 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $130 |
| Novo Nordisk Inc | 1 | $125 |
| KYOWA KIRIN, INC. | 1 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $118 |
Products named: RELTONE 200 MG, AIRSUPRA, TYVASO, Repatha, Veozah, VRAYLAR, LUMRYZ, Wegovy.
Industry payments across NV — which companies pay providers there.
